Experimental science, however, demands that one establishes a cause and effect relationship. There is no known cure of Alzheimer's disease, so one cannot refer to experimental medicine for an answer, with the exception of inherited dominant genetic mutations that impact only a small number of people. Unfortunately, of these mutations, those affecting the APP gene do not cause neuronal loss in mice; so the mouse models are inherently problematic.
This editorial calls for a clinical trial for antimicrobials in this disease. While I doubt that Alzheimer's is caused by infectious agents, there really is no harm in trying (except perhaps to the pockets of the trial's sponsors). In fact a trial of the antibiotic minocycline was completed in 2014 [1], however the results do not appear to have been reported.
I would go further. In my medical research work I saw dozens, probably hundreds of "statistically significant" correlations between different variables in a rather small dataset. I found them just by taking different subsets or summarizing the same data in a few different ways.
I didn't find any interesting and so published nothing about them, but I am sure others could build entire careers out of coming up with narratives to explain those correlations.
I have to think that people who have trouble finding correlations are either clueless about exploring the data (eg have only ever looked at dynamite plots of their results) or are measuring something so swamped by instrumental noise it is meaningless.
Bredesen DE. Reversal of cognitive decline in Alzheimer's disease. Aging (Albany NY). 2016 Jun;8(6):1250-8. doi: 10.18632/aging.100981.
Bredesen DE. Reversal of cognitive decline: A novel therapeutic program. Aging (Albany NY). 2014; 6:707-17. doi: 10.18632/aging.100690.
The number of patients studied is too few, i.e. is grossly underpowered statistically, and the results do not allow any general conclusion to be drawn.
https://www.sciencebasedmedicine.org/mend-protocol-for-alzhe...
The commercialization of the MEND protocol might have run into some partnership issues between the original researcher and the first company he worked with dispensing the treatment:
http://www.prnewswire.com/news-releases/dr-dale-bredesen-ann...
Here is a more layman-friendly description of the MEND protocol.
My intuition is that it is more likely caused by an infection than that it is just a malfunction caused by random chance
If it is caused by a specific infection, then one would expect such a specific infection to cause the disease in young as well as older people.
Neither of these scenarios are known to occur.
If you extend beyond these simple scenarios, then you have to assume that there is another (unknown) factor that induces Alzheimer's disease, and therefore that the theory of infectious disease causing this condition is not sufficient.
Hence statements like "We can't keep ignoring the evidence", "landmark editorial", etc.
Or to taxpayers when some pharmaceutical company finds a specious statistical correlation between Alzheimer's and an infectious agent that one of their products happens to treat.
A cynical view, yes. Borne out of my reading of Bad Pharma and coming across at least one startup whose business model was to do this with genetic tests.
My wife studies Alzheimer's and I hope she will respond here, but I'm afraid she gets too angry by sensationalist stories based on editorials rather than mainline research.
Of course there is inflammation involved. From what I understand talking with her, there is not much mechanistic work done with human tissue; most of it is with mouse models that can only get parts of the disease.
Interesting to check out: the inflammasome: https://en.m.wikipedia.org/wiki/Inflammasome.
Alzheimer's is as inflammation-driven as, say, heart disease. Which is to say that inflammation is a meaningful contributing factor along with all the other meaningful contributing factors. This is primarily these conditions are linked with obesity, because visceral fat is a major source of inflammation.
E.g.:
http://www.southampton.ac.uk/news/2016/01/blocking-brain-inf...
http://www.manchester.ac.uk/discover/news/treatment-option-f...
"Professor Resia Pretorius of the University of Pretoria"
founding a city to start your own University sixty years later to publish a paper another hundred years later, that's what I call the long-con.
> We refer to the many studies, mainly on humans, implicating specific microbes in the elderly brain, notably herpes simplex virus type 1 (HSV1), Chlamydia pneumoniae, and several types of spirochaete, in the etiology of AD.
the sample size was not huge (14 i think) and it was cited nitrates are the beneficial agent. It would be interesting to see if there is any association between the suggested offending microbial activity and nitrates in vitro before moving on to some sort of in vivo model
https://www.sciencedaily.com/releases/2010/11/101102130957.h...
1. Exercise for oxygen
2. Gum disease
3. Standing up and feeling a head rush
4. blood sugar and diabetes
If we can believe each of these 4 is the key insight within 12 months, I have to wonder at the state of our knowledge about the disease.
No.
To wit, the hypothesis presented in the post linked to by OP can be tested by treating people with Alzheimer's disease with antimicrobial agents.
Unfortunately, in what concern people (disease and dying) experiments on humans (aka clinical trials) are expensive, with uncertain returns. So the experiments that could test hypotheses concerning Alzheimer's disease in real actual people are rarely performed to the level statistically needed.
Instead we get a plethora of studies in mice with "suggestive"implications for what might occur in humans. Along with random studies that are not worth more than anecdotes (see those I commented on above).